Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I

OBJECTIVES: Studies 1878 and 1844 demonstrated non-inferior efficacy of switching suppressed HIV-1-infected adults to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) versus continuing boosted PI-based triple regimens or dolutegravir/abacavir/lamivudine (DTG/ABC/3TC). Here, detailed ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Andreatta, Kristen, Willkom, Madeleine, Martin, Ross, Chang, Silvia, Wei, Lilian, Liu, Hui, Liu, Ya-Pei, Graham, Hiba, Quirk, Erin, Martin, Hal, White, Kirsten L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857193/
https://www.ncbi.nlm.nih.gov/pubmed/31430369
http://dx.doi.org/10.1093/jac/dkz347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857193/
https://www.ncbi.nlm.nih.gov/pubmed/31430369
http://dx.doi.org/10.1093/jac/dkz347

Ejemplares similares